2-Bromomalonaldehyde Market | Target Markets, Regional Demand and Supplier Structure

2-Bromomalonaldehyde Market Availability and Buyer Access Remain Tied to Pharmaceutical Intermediate Demand

The global 2-Bromomalonaldehyde market is estimated at USD 18.4 million in 2026 and is projected to reach USD 28.9 million by 2033, reflecting a CAGR of 6.7% during the forecast period. This is a narrow-volume, specification-driven intermediate market rather than a broad commodity chemical category. Buyer access is concentrated among pharmaceutical intermediate buyers, medicinal chemistry laboratories, custom synthesis firms, catalogue chemical distributors, and API-route development teams. Availability is strongest in China, Japan, India, Europe, and the United States through catalogue pack suppliers, custom manufacturing houses, and bulk quotation channels. Demand is mainly linked to heterocyclic compound synthesis, pyrimidine chemistry, imidazole derivatives, and tegoprazan-related intermediate use, while the supply side remains fragmented across small-pack laboratory suppliers and Asian bulk producers.

2-Bromomalonaldehyde Availability Is Stronger in Catalogue and Custom-Synthesis Channels Than in Open Commodity Trade

2-Bromomalonaldehyde does not behave like a solvent, resin input, brominated flame retardant, or high-volume aldehyde. It is purchased in grams, hundreds of grams, kilograms, and selective bulk lots depending on whether the buyer is conducting route screening, pilot development, clinical-stage synthesis, or commercial intermediate sourcing. This makes availability visible through research chemical catalogues, but true market access depends on documentation, purity assurance, cold-chain handling, and supplier willingness to quote for regulated pharmaceutical use.

Major buyer access points include Merck/Sigma-Aldrich, TCI, Thermo Fisher/Alfa Aesar, BLD Pharm, Biosynth, Huateng Pharmaceutical, Accela ChemBio, ChemicalBook-listed Chinese manufacturers, and specialist intermediates suppliers. Catalogue availability is typically positioned at 97% to above 98% purity, while Chinese bulk listings commonly quote 98% to 99% purity. TCI lists bromomalonaldehyde with more than 98.0% GC purity and identifies it as a frozen-storage, inert-gas-handled, air-sensitive and moisture-sensitive solid. This matters commercially because distributors with controlled storage and documentation can serve pharma R&D buyers faster than low-cost producers that require fresh quotation, technical review, or export handling.

Buyer access is also split by pack size. Laboratory buyers use 1 g, 5 g, 25 g, and 50 g packs for route work, whereas custom synthesis firms and intermediate traders quote 1 kg, 5 kg, 10 kg, 25 kg, and occasionally 100 kg or higher. Chinese supplier listings in 2026 show more than 300 supplier entries, with example offers ranging from USD 70 to USD 700 per kg and minimum order quantities around 10 kg for some listings. That wide spread reflects uneven quality documentation, batch availability, purity claims, export readiness, packaging, and supplier credibility rather than a single transparent market price.

Pharmaceutical Intermediate Buyers Account for the Strongest Demand Concentration

The strongest demand concentration comes from pharmaceutical intermediate users because 2-Bromomalonaldehyde is used as a building block in heterocyclic chemistry and is specifically marketed by some suppliers as a tegoprazan intermediate. Huateng Pharmaceutical lists 2-Bromomalonaldehyde, CAS 2065-75-0, as an intermediate of tegoprazan and offers it for R&D, evaluation, pilot, and commercial requirements. This gives the product a more defined demand base than general aldehyde intermediates, where end-use mapping is often diffuse.

Tegoprazan-related expansion is relevant because the downstream drug is moving across more geographies. In September 2025, HK inno.N announced the India launch of K-CAB under the PCAB brand with Dr. Reddy’s Laboratories managing local sales and marketing. India was described as the fourth-largest peptic ulcer treatment market globally, valued at around KRW 1.52 trillion in 2024, and GERD prevalence was estimated at about 38% of the population. This does not convert directly into equivalent 2-Bromomalonaldehyde tonnage, but it supports intermediate qualification, second-source sourcing, and route-stability demand from suppliers serving the P-CAB value chain.

China is another demand anchor. In October 2024, RaQualia Pharma announced that Shandong Luoxin Pharmaceutical received Chinese marketing approval for tegoprazan use in Helicobacter pylori eradication therapy. The relevance for 2-Bromomalonaldehyde is supply-route continuity: when a downstream active drug adds indications or dosage-form expansion, intermediate suppliers face more inquiries for purity, impurity profile, batch reproducibility, and regulatory support.

Channel Reach Is Fragmented, but Asia Controls Bulk Access

Asia dominates practical bulk access because China has the deepest supplier base and India has a large pharma-intermediate procurement ecosystem. ChemicalBook’s China supplier listings show hundreds of 2-Bromomalonaldehyde supplier entries across Shanghai, Jiangsu, Hubei, Zhejiang, Shandong, Henan, Guangdong, and other provinces. This makes China the most visible sourcing hub for kilogram-level and custom-manufactured material.

Japan and the United States are stronger in catalogue reliability and documentation access rather than bulk price competitiveness. TCI’s India-facing catalogue indicates dispatch from Hyderabad stock on the same day when local inventory is available, while Japan warehouse stock is typically dispatched in 10–12 working days. Thermo Fisher and Sigma-Aldrich provide research-use access in small packs, which supports universities, CROs, medicinal chemistry teams, and early-stage biotech buyers.

Segment Behavior Shows Two Different Markets Inside One Chemical

The market has two practical segments. The first is the small-pack research segment, where buyers pay for documentation, traceability, speed, and low-volume convenience. This segment is less price-sensitive and more dependent on catalogue trust, safety data, certificates of analysis, and procurement-system access.

The second is the kilogram-to-bulk intermediate segment, where price, batch history, synthetic route, impurity control, export compliance, and supplier auditability decide adoption. Pharma buyers do not shift suppliers only because a lower price is quoted. For a moisture-sensitive brominated aldehyde intermediate, failed batch consistency can disrupt synthesis campaigns, create impurity investigation costs, or delay downstream validation.

Market Constraints Are Linked to Specification, Handling, and Limited End-Use Breadth

The largest constraint is not lack of suppliers; it is supplier qualification. Many listings show availability, but fewer suppliers can support regulated pharmaceutical procurement with stable purity, impurity documentation, packaging consistency, and repeat-batch reliability. The second constraint is handling. 2-Bromomalonaldehyde is commonly described as air-sensitive, moisture-sensitive, heat-sensitive, and requiring frozen or controlled storage. This raises logistics complexity for buyers outside major chemical distribution corridors.

The third constraint is narrow demand breadth. Unlike formaldehyde, acetaldehyde, or common brominated intermediates, this product depends heavily on medicinal chemistry and selected heterocyclic synthesis. Growth is therefore real but bounded. Market expansion follows pharmaceutical route adoption, tegoprazan commercialization, CRO activity, and custom synthesis demand rather than mass chemical consumption.

China-Led Bulk Supply and India-Led Pharma Procurement Shape Regional Access

Regional availability in the 2-Bromomalonaldehyde market is led by Asia, but the buying logic is different across countries. China has the broadest visible supplier base for kilogram and bulk lots, while India is stronger as a buyer-access market because of its API, pharmaceutical intermediate, and contract synthesis ecosystem. Europe, Japan, and the United States remain important for catalogue-grade access, documentation-heavy procurement, and laboratory demand.

China’s role is mainly supply-side. Multiple suppliers across Shandong, Hubei, Jiangsu, Zhejiang, Shanghai, Guangdong, and Henan offer 2-Bromomalonaldehyde in 98% to 99% purity bands. Listings show packaging options from 1 kg and 5 kg laboratory-transition packs to 25 kg, 50 kg, 100 kg, 200 kg, and tonne-scale quotation formats. This supplier density gives Chinese producers the strongest role in price discovery and emergency sourcing. However, not every listed producer can support repeat-batch pharmaceutical qualification, which keeps audited suppliers at a premium.

India is more demand-facing. Hyderabad, Telangana, Gujarat, and Maharashtra have dense pharma-intermediate procurement networks, and Indian supplier listings show pack formats of 1 kg, 5 kg, 10 kg, 25 kg, 100 kg, and 1 MT. This reflects a market where CROs, CDMOs, generic-drug route developers, and intermediate traders need both sample-level material and pilot-quantity supply. The September 2025 launch of tegoprazan in India under Dr. Reddy’s commercial channel increases the relevance of Indian sourcing discussions, especially for firms evaluating second-source intermediates and route-security options.

Japan and South Korea influence the market through pharmaceutical innovation rather than large open-market chemical supply. South Korea’s connection is strongest through tegoprazan commercialization, while Japan’s contribution is higher through high-purity research chemical distribution and established fine-chemical catalogues. Japanese suppliers are preferred where buyers need consistent certificates of analysis, controlled storage, and technical trust more than the lowest landed cost.

Distribution Structure Depends on Pack Size, Documentation, and Temperature Control

Distribution is split between catalogue sales, distributor-assisted imports, and direct manufacturer quotation. Small-pack access is dominated by established catalogue suppliers. These suppliers typically serve universities, pharmaceutical discovery teams, diagnostic chemistry users, and medicinal chemistry laboratories. Their advantage is not cost per kilogram; it is low transaction friction, documentation, safety data, and procurement compatibility.

Bulk access follows a different pattern. Buyers usually ask for certificates of analysis, HPLC or GC purity, impurity profile, batch size, available stock, lead time, storage declaration, and export documentation before placing an order. Since 2-Bromomalonaldehyde is air-sensitive, moisture-sensitive, and heat-sensitive, buyers also evaluate whether the material can be shipped under controlled conditions. Storage requirements below 0°C or below -15°C create additional handling cost and limit supplier choice for buyers in countries without mature specialty chemical logistics.

Segmentation is therefore better understood by access route rather than only purity grade:

• Catalogue-grade 2-Bromomalonaldehyde: Used by R&D laboratories, academic groups, and early-stage pharma teams; usually purchased in 5 g, 25 g, and 50 g packs.
• Kilogram-grade intermediate supply: Used by CROs, CDMOs, and route-development buyers; typically evaluated through sample approval before repeat purchase.
• Bulk pharmaceutical-intermediate supply: Used where downstream synthesis demand is established; buyer approval depends on repeatability, impurity control, packaging, and audit readiness.
• Custom synthesis and made-to-order supply: Used when buyers need route-specific impurity limits, confidential synthesis support, or larger lots with controlled release timelines.

Customer Buying Pattern Is Qualification-Led, Not Spot-Price-Led

Customer access is strongest where procurement teams can combine three things: supplier screening, technical documentation, and cold-chain or controlled-storage logistics. Pharma buyers do not treat 2-Bromomalonaldehyde as an interchangeable catalogue chemical once it enters a validated synthesis route. Even when lower prices are available from smaller producers, buyers prefer suppliers that can repeat the same assay, impurity profile, appearance, and packaging condition across batches.

Replacement behavior is limited because the chemical is not installed equipment or a consumable used at fixed intervals. Demand is campaign-driven. Orders rise when medicinal chemistry screening, intermediate validation, pilot synthesis, or downstream drug commercialization requires fresh batches. This makes the market uneven by quarter but relatively sticky once a supplier is qualified. The strongest customers are API-route developers, custom synthesis companies, pharmaceutical intermediate traders, research chemical distributors, and medicinal chemistry laboratories working on heterocyclic compounds, pyrimidine chemistry, guanine adduct research, and tegoprazan-related synthesis routes.

Supplier Ecosystem Is Fragmented, with Trust Concentrated Around Documentation and Repeat-Batch Reliability

The 2-Bromomalonaldehyde supplier ecosystem has two layers. The first layer consists of global catalogue and fine-chemical suppliers that provide reliable access for research and early-stage development. The second layer consists of regional Chinese and Indian manufacturers, traders, and custom synthesis firms that compete in kilogram and bulk supply. No single supplier publicly controls a dominant share of the market, and available evidence points to a fragmented supplier base where buyer trust depends on assay reliability, storage handling, and documentation rather than brand visibility alone.

Sigma-Aldrich/Merck has strong catalogue visibility for bromomalonaldehyde at 97% assay, making it relevant for research laboratories, universities, and early-stage synthesis teams. Its advantage is procurement integration, safety documentation, small-pack availability, and buyer trust among institutional chemical users. The company is better positioned in the small-pack and documentation-led segment than in price-sensitive bulk sourcing.

TCI is another high-trust supplier because it lists bromomalonaldehyde with purity above 98.0% by GC, frozen storage below 0°C, inert-gas handling, and sensitivity to air, moisture, and heat. These details matter because the product’s handling profile makes cold storage and controlled shipment part of the commercial offer. TCI’s role is strongest in Japan, India, Southeast Asia, Europe, and North America where laboratories and pharma buyers need validated catalogue access before moving to larger sourcing.

Thermo Fisher Scientific/Alfa Aesar participates through research chemical distribution, with 25 g and 50 g pack visibility in the 97% purity band. This positions the company toward academic, analytical, medicinal chemistry, and pharmaceutical R&D buyers. Its competitive advantage is global procurement access rather than large-volume cost leadership.

Biosynth provides catalogue, bulk, and custom product access for life-science and diagnostics users. Its positioning is useful for buyers that need non-standard quantities, documentation, or custom quotation rather than simple online checkout. Biosynth’s listing also identifies long-term storage below -15°C, which supports the view that supplier capability is tied to controlled storage and not only synthesis availability.

BLD Pharm, Ambeed, Accela ChemBio, and other specialist chemical platforms operate in the mid-layer between catalogue and custom quotation. Their strength lies in broad organic intermediate catalogues, technical document access, quote-based procurement, and ability to support research-to-kilogram transition. These companies are relevant where buyers need faster screening, technical documents, and international shipment options.

China-based producers and exporters represent the widest supply base. ChemicalBook-listed suppliers include XPERTICK (Shandong) Bio-Pharmaceutical, Hangzhou Junjieriheng New Materials, Hubei Long Kang Sheng Fine Chemical, Cangzhou Enke Pharma Tech, New Energy Chemicals, Shandong Fengyang Technology, and other regional producers. Many quote 98% to 99% purity and pack sizes from 1 kg to 25 kg, 50 kg, 100 kg, 200 kg, and tonne-scale options. Their advantage is cost, availability, and willingness to quote larger lots. Their limitation is uneven buyer confidence unless documentation, auditability, and repeat-batch quality are proven.

India’s supplier ecosystem includes Tanuj Pyridine, Chaturya Biotech, Prodev Pharma, Altrakem Pharma Life Sciences, Rivashaa Agrotech Biopharma, and Telangana- or Hyderabad-based reagent and intermediate suppliers. India is relevant because the country combines domestic pharmaceutical demand, API-route development, export-oriented CDMO activity, and distributor networks that can handle gram-to-kilogram movement. Indian suppliers are better positioned when buyers need local access, faster commercial discussions, and reduced import dependency.

Pricing behavior reflects the split between small-pack trust and bulk negotiation. Public catalogue prices show a very high per-gram cost in 5 g to 25 g packs, while Chinese and Indian bulk quotations can move sharply lower per kilogram. The gap is not only margin; it reflects packaging, documentation, controlled storage, small-batch handling, distributor overhead, compliance support, and buyer convenience. For pharmaceutical users, the cheapest quote is not automatically the best supply option because a failed or inconsistent batch can cost more than the raw-material saving.

Recent market-linked developments include:

• April 2026: Public catalogue listings showed bromomalonaldehyde price visibility across Sigma-Aldrich and TCI pack sizes, with 5 g and 25 g laboratory packs actively listed, confirming continuing small-pack buyer access.
• June 2026: ChemicalBook supplier data showed China-based producers quoting 98% to 99% purity with kilogram-to-bulk packaging, including 25 kg, 50 kg, 100 kg, 200 kg, and tonne-scale formats.
• September 2025: Dr. Reddy’s Laboratories launched tegoprazan in India under the PCAB brand for acid-related gastrointestinal diseases, strengthening downstream relevance for tegoprazan-related intermediate supply.
• September 2025: HK inno.N confirmed K-CAB’s entry into the Indian GERD treatment market through Dr. Reddy’s, adding a large pharma-demand geography to the tegoprazan ecosystem.
• August 2025: A WIPO publication related to tegoprazan key intermediate preparation signaled continued process-development activity around the downstream pharmaceutical route.
• October 2024: Shandong Luoxin Pharmaceutical received Chinese approval for tegoprazan use in Helicobacter pylori eradication therapy, supporting broader downstream demand visibility in China.

Other recently published reports:

Fatty Acids and Their Salts Market